報價延遲最少15分鐘:2025/12/19 17:51 EST
盤後時段
|
||||
|
3.78 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.73
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.41/-1.01
|
|
企業價值
604.75M
|
| 資產負債 |
|
每股賬面淨值
-1.92
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
70.84M
|
|
每股收益
0.99
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more linesof systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed byEurope, the Middle East and Africa (EMEA). |
